<DOC>
	<DOCNO>NCT00056329</DOCNO>
	<brief_summary>The goal study determine safety efficacy administration vitamin E , show delay progression Alzheimer 's disease , slow rate cognitive/functional decline older person Down syndrome .</brief_summary>
	<brief_title>Vitamin E Aging Persons With Down Syndrome</brief_title>
	<detailed_description>The grow success therapeutic intervention ( include antioxidant Vitamin E ) Alzheimer 's disease general population require solution methodological problem therapeutic trial conduct age population Down syndrome ultimately improve quality life well family caregiver . The experience gain trial useful design appropriate cognitive measure Alzheimer 's disease person Down syndrome subsequent trial . The goal international three-year study determine whether administration vitamin E , show delay progression Alzheimer 's disease , slow rate cognitive/functional decline person age 50 old Down syndrome . Persons Down syndrome functioning level intellectual disability eligible . Men woman approximately equal number people minority ethnic group Caucasian include . A total 350 individual Down syndrome , 50 year age old , recruit approximately 21 trial site . The study randomize , double-blind , placebo-controlled , parallel group design stratification geographic site presence Alzheimer disease accord DSM-IV ( American Psychiatric Association ) criteria diagnose disease . Apolipoprotein E ( Apo E ) genotype determine screen visit allow secondary analysis impact Apo E genotype ( may influence Alzheimer 's disease risk ) outcome measure response treatment . DNA specimen also store possible future genetic analysis , trial site allow non-participation procedure . Visits occur baseline 6 monthly interval , visit include interval medical history , current interval medication , side effect checklist , adverse event , pill count , institutionalization status , cognitive , functional , behavioral measure , DSM-IV diagnostic assessment Alzheimer 's disease .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>Presence clinically determine Down syndrome ( karyotypes optional ) . Medically stable . Medications stable 3 month . Appropriately sign witnessed consent form . Involvement/cooperation informant/caregiver . Medical/neurological condition ( Alzheimer 's disease ) associate dementia . Brief Praxis Test score &lt; 20 . Modified Hachinski score &gt; 4 . Major depression within 3 month . History disorder blood coagulation ( inherit acquire ) . Current use anticoagulant . Use experimental medication within 3 month . Regular use vitamin E great 50 unit per day previous 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Aging Persons</keyword>
	<keyword>Down Syndrome</keyword>
	<keyword>Vitamin E</keyword>
	<keyword>Alzheimer disease</keyword>
</DOC>